Anzeige
Mehr »
Login
Dienstag, 19.03.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Der Zug verlässt den Bahnhof - Umringt von potenziellen Käufern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 891460 | ISIN: AU000000IMU9 | Ticker-Symbol: N/A
1-Jahres-Chart
IMUGENE LIMITED Chart 1 Jahr
5-Tage-Chart
IMUGENE LIMITED 5-Tage-Chart

Aktuelle News zur IMUGENE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.03.IMUGENE LIMITED: Imugene progresses onCARlytics solid tumour trial to combination arm2
11.03.Imugene Limited: Phase 1 onCARlytics solid tumour trial advances to combination arm treatment205The OASIS trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by CD19-targeting therapeutics such as Amgen's Blincyto®, Gilead's...
► Artikel lesen
11.03.Imugene's onCARlytics clears Phase 1 milestone in solid tumour therapy trial2
10.03.IMUGENE LIMITED: Phase 1 onCARlytics Trial Advances to Combination Arm-
27.02.IMUGENE LIMITED: Half Yearly Report and Accounts1
22.02.Imugene Limited: Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts3
15.02.IMUGENE LIMITED: Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial1
15.02.Imugene doses first patient in onCARlytics trial targeting cancer with novel approach1
13.02.IMUGENE LIMITED: Phase 1 onCARlytics Trial Doses First Intravenous Patient-
02.02.IMUGENE LIMITED: Notice of change of interests of substantial holder - PH2
01.02.IMUGENE LIMITED: Change of Director's Interest Notice - PH3
01.02.IMUGENE LIMITED: Cleansing Notice2
01.02.IMUGENE LIMITED: Application for quotation of securities - IMU2
01.02.IMUGENE LIMITED: Application for quotation of securities - IMU2
29.01.IMUGENE LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report1
23.01.MaxCyte rises on collaboration with Imugene for cancer medicines2
23.01.MaxCyte Signs SPL Agreement With Imugene1
23.01.MaxCyte, Inc: MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs1
19.01.IMUGENE LIMITED: Change of Director's Interest Notice x6-
19.01.Imugene's novel cancer treatment enters new phase in MAST trial1
Seite:  Weiter >>
112 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1